□ Overview
Yunnan Watson Biotechnology Co., Ltd. is a specializing in human vaccine development, production and sales of bio-pharmaceutical company dedicated to providing safe and effective domestic and international markets, excellent quality, technologically advanced human vaccine products.
In Kunming National Hi-tech Zone has an advanced new vaccines research and development center and pilot base in Taizhou, Jiangsu High-tech Zone Yuxi Chinese medicine into modern urban construction of vaccine production base, build a cover 29 domestic provinces and cities, more than 2,000 counties of the marketing network.
2010 year 11 12, Yunnan Watson Biotechnology Co., Ltd. (Stock code: Watson organisms; stock code: 300 142) was listed on the Shenzhen Stock Exchange, becoming the first in China's Yunnan Province, the GEM listing listed companies.
□ performance
2009, the company achieved operating income of self-produced vaccine business 20,057.82 million, net profit of 8,094.39 million; 2010, the company achieved operating income of 358,792,300 yuan, net profit 15441.66 million, compared with last year are to maintain rapid growth. With the follow-up reserves the gradual self-developed products listed in the next few years, performance of the company will maintain a sustained growth.
□ Product
in the field of vaccine research and development leads the industry has so far developed 13 broad market prospects of vaccine products, product research project in the past 20. Among them, two products that Haemophilus influenzae type b conjugate vaccine and lyophilized A, C meningococcal polysaccharide conjugate vaccine has been marketed, and achieved good results. In addition to complete clinical research clinical research compliance report obtained six products, two products that freeze-dried A, C, Y, W135 Meningococcal meningitis and freeze-dried polysaccharide vaccine A, C Meningococcal meningitis polysaccharide vaccine production plant has been completed and trial production is being applied by the pharmaceutical production of documents, about the market in the near future. Without cell DPT triple vaccine production line has been completed trial production stage are debugging, children and adult-type influenza virus vaccine production plant has entered the building construction phase. Follow-up workshop is being planned production design.
2011 onwards, with large reserves of mature products, the company will enter a new round of construction of new production peak. Watson's results of operations will also be biological follow-up because a lot of new products to market and will usher in a new round of rise.
□ team
company's business and management team all have nearly two decades of professional background in the vaccine industry, the vaccine industry chain with a deep understanding and keen market insight, and rich practical experience and professional management. After decades of development, the company has formed a unified development strategy, mission vision and values, and to develop and exercise a large number of young technology and management backbone for the company's future development has laid a solid foundation.
□ Honor
company is a national high-tech enterprise, is a national vaccine research and development centers of enterprises and the vaccine industry demonstration base. The company has an independent commitment to the Ministry of Science, "863" major research issue 3, the National Development and Reform Project 2 high-tech industry, the Ministry of Health Communicable Disease Prevention major project, the Ministry of Science and support programs and international cooperation projects and 1 items, Yunnan Province, Kunming, more than 10 scientific and technological projects.
Present the company is the only combination of a bacterial vaccine also has two marketed vaccines business.